Collas Crill has advised Curaleaf on its acquisition of medicinal cannabis specialist EMMAC Life Sciences at an implied post-money valuation of $413m.
Collas Crill's role included advising on the establishment in Guernsey of Curaleaf International Holdings to hold the EMMAC investment and further its European expansion.
Curaleaf International already has an operational presence in EU countries that are enacting new medical cannabis access schemes.
The company intends to substantially increase its cultivation capacity in 2021 to facilitate anticipated growth through increased access to the use of cannabis across major European and export markets.
Partner Paul Wilkes and Senior Associate Gareth Morgan led Collas Crill's advisory team.